Hybrid PET/CT in Cancer Patients

This study has been completed.

First Received: November 7, 2006 Last Updated: April 10, 2007 History of Changes

Sponsored by:	Rambam Health Care Campus
Information provided by:	Rambam Health Care Campus
ClinicalTrials.gov Identifier:	NCT00396916

Purpose

The purpose of the present study is to assess the role of hybrid PET/CT imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. The clinical impact of PET/CT in the management and treatment of these two groups of cancer patients will be evaluated

Condition	Intervention
Cancer	Device: PET/CT imaging

Study Type:	Interventional
Study Design:	Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title:	The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin

Resource links provided by NLM:

MedlinePlus related topics: Cancer

U.S. FDA Resources

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:

the impact of the imaging modality on patient management

Secondary Outcome Measures:

the impact of the imaging modality on patient management

Estimated Enrollment:	45
Study Start Date:	December 2004

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Cancer patients in complete remission after treatment, with serial elevation of serum tumor markers and negative CT or other conventional imaging test.
Patients with newly diagnosed metastatic cancer with unknown primary tumor
Glucose levels below 150-200
Patient signed informed consent

Exclusion Criteria:

Pregnant or lactating women
Patient unable or not willing to tolerate the test until its completion
One or more of the inclusion criteria is not fulfilled

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00396916

Locations

Israel
Rambam Medical Center
Haifa, Israel

Sponsors and Collaborators

Rambam Health Care Campus

Investigators

Principal Investigator:

Rachel Bar-Shalom, MD

Rambam Health Care Campus

More Information

No publications provided

Study ID Numbers:	hybridCTIL
Study First Received:	November 7, 2006
Last Updated:	April 10, 2007
ClinicalTrials.gov Identifier:	NCT00396916 History of Changes
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:

cancer patients

Study placed in the following topic categories:

Neoplasm Metastasis

ClinicalTrials.gov processed this record on September 01, 2009